- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07537881
En klinisk fase I/II-studie for å evaluere sikkerheten og effekten av RC288 i behandlingen av solide tumorer
En multicentrisk fase I/II klinisk studie for å evaluere sikkerheten og effekten av RC288 for injeksjon i behandlingen av lokalt avansert uopererbar eller metastatisk ondartet solid svulst.
The primary objective is to evaluate the safety and tolerability of RC288; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC288; and determine the recommended phase 2 dose (RP2D), and assess the efficacy of RC288 at the RP2D dose;
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Heping Liu
- Telefonnummer: +8610-65384976
- E-post: heping.liu@remegen.com
Studiesteder
-
-
Changsha
-
Hunan, Changsha, Kina
- Har ikke rekruttert ennå
- Hunan Cancer Hospital
-
Ta kontakt med:
- Lin Wu
-
-
Chengdu
-
Sichuan, Chengdu, Kina
- Har ikke rekruttert ennå
- Sichuan Cancer Hospital & Institute
-
Ta kontakt med:
- Huangming Hong
-
-
Fuzhou
-
Fujian, Fuzhou, Kina
- Har ikke rekruttert ennå
- Fujian Cancer Hospital
-
Ta kontakt med:
- Zhangzhou Huang
-
Fujian, Fuzhou, Kina
- Har ikke rekruttert ennå
- Fujian Medical University Union Hospital
-
Ta kontakt med:
- Jinhuo Lai
-
-
Guangzhou
-
Guangdong, Guangzhou, Kina
- Har ikke rekruttert ennå
- Sun Yat sen University Cancer Center
-
Ta kontakt med:
- Yanxia Shi
-
Ta kontakt med:
- Yonghong Li
-
-
Guiyang
-
Guizhou, Guiyang, Kina
- Har ikke rekruttert ennå
- The Affiliated Hospital of Guizhou Medical University
-
Ta kontakt med:
- Huixin Ge
-
-
Haerbin
-
Heilongjiang, Haerbin, Kina
- Har ikke rekruttert ennå
- Harbin Medical University Cancer Hospital
-
Ta kontakt med:
- Baogang Liu
-
-
Hunan
-
Changsha, Hunan, Kina
- Rekruttering
- Hunan Cancer Hospital
-
Ta kontakt med:
- Weiqing Han
- Telefonnummer: +86731-89762271
- E-post: md70210@sina.com
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina
- Rekruttering
- Nanjing Drum Tower Hospital
-
-
Jinan
-
Shandong, Jinan, Kina
- Har ikke rekruttert ennå
- Cancer Hospital of Shandong First Medical University Cancer Hospital
-
Ta kontakt med:
- Juan Li
-
Ta kontakt med:
- Benkui Zou
-
Shandong, Jinan, Kina
- Rekruttering
- Shanxi Cancer Hospital
-
-
Shanxi
-
Shanxi, Shanxi, Kina
- Rekruttering
- Shanxi Cancer Hospital
-
-
Taizhou
-
Zhejiang, Taizhou, Kina
- Har ikke rekruttert ennå
- Taizhou Hospital of Zhejiang Province
-
-
Wenzhou
-
Zhejiang, Wenzhou, Kina
- Har ikke rekruttert ennå
- The First Affiliated Hospital of Wenzhou Medical University
-
Ta kontakt med:
- Wei Chen
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Voluntarily participate in this study, sign the informed consent form, and be able to adhere to the study protocol;
- Age between 18 and 75 years (including 18 and 75 years);
- ECOG PS score of 0 or 1;
- Expected survival ≥12 weeks;
- According to RECIST v1.1 criteria, based on imaging examinations, there is at least one measurable target lesion;
- Sufficient bone marrow, liver, kidney, and blood clotting function
Exclusion Criteria:
- Pregnant, breastfeeding, or intending to become pregnant subjects.
- Subjects with brain metastases.
- Subjects with unresolved toxicities from prior anti-tumor therapy not recovered to NCI-CTCAE v6.0 Grade 1.
- Subjects with known hypersensitivity or delayed allergic reactions to any component of the investigational drug or similar drugs.
- Subjects with acute, chronic, or symptomatic infections.
- Subjects with uncontrolled cardiovascular diseases.
- Subjects with confirmed or suspected interstitial lung disease (ILD), drug-related pneumonia, radiation pneumonitis, severely impaired pulmonary function, or other pulmonary diseases.
- History of underlying pulmonary disease.
- Subjects with a history of cirrhosis (Child-Pugh B or C class).
- Clinically significant gastrointestinal disease.
- Subjects with uncontrolled diabetes (HbA1c ≥ 10%).
- Occurrence of hemorrhagic events of Grade ≥2 per NCI CTCAE (v6.0) within 4 weeks prior to screening; or clinical manifestations suggestive of a significant bleeding tendency within 4 weeks prior to screening.
- Imaging during the screening period shows tumor invasion or involvement of vital organs, with imaging evidence judged by the investigator to indicate a risk of bleeding or fistula formation.
- History of arterial/venous thromboembolic events within 6 months prior to the first dose.
- Presence of pericardial effusion or cardiac tamponade, or third-space fluid accumulation that, in the investigator's judgment, cannot be stably controlled by drainage or other methods.
- History of active autoimmune disease requiring systemic therapy within the past 2 years.
- History of other invasive malignancies within 5 years prior to the first dose, or evidence of residual disease from any previously diagnosed malignancy.
- History of other acquired or congenital immunodeficiency diseases, or history of organ transplantation.
- History of or current poorly controlled psychiatric disorder.
- Poor compliance, and patients who are expected to be unable to cooperate with the completion of trial procedures.
- Presence of any other disease, metabolic abnormality, physical examination finding, or laboratory abnormality that, in the investigator's judgment, gives reasonable suspicion of a condition that contraindicates the use of the investigational drug, may affect the interpretation of study results, or places the patient at high risk.
- Local or systemic diseases not caused by malignancy, or diseases or symptoms secondary to the tumor, which may lead to higher medical risks and/or uncertainty in survival assessment.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: RC288 (Phase I, dose escalation)
There are six predefined escalating dose levels. |
Intravenous (IV) administration of RC288. Patients will continue treatment until unacceptable toxicities, disease progression, or any criterion for withdrawl from the study. |
|
Eksperimentell: RC288 (Phase II, dose expansion)
In the multi-indication cohort expansion phase, further assess the efficacy and safety of RC288 in various cancer types using the RP2D. |
Intravenous (IV) administration of RC288. Patients will continue treatment until unacceptable toxicities, disease progression, or any criterion for withdrawl from the study. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Dosebegrensende toksisitet (DLT)
Tidsramme: 24 måneder
|
24 måneder
|
|
Forekomst og alvorlighetsgrad av bivirkninger/alvorlige bivirkninger (gradert i henhold til NCI CTCAE v6.0)
Tidsramme: 24 måneder
|
24 måneder
|
|
Fastsett RP2D for RC288
Tidsramme: 24 måneder
|
24 måneder
|
|
MTD og/eller MAD
Tidsramme: 24 måneder
|
24 måneder
|
|
Prostatakreft-kohort: Undersøkerens vurdering av ORR i henhold til RECIST v1.1-kriterier og PCWG3-kriterier
Tidsramme: 24 måneder
|
24 måneder
|
|
Ikke-prostatakreft-kohort: Undersøker vurdert ORR i henhold til RECIST v1.1-kriterier
Tidsramme: 24 måneder
|
24 måneder
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- RC288-C101
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .